American International Group Inc. Lowers Position in Enanta Pharmaceuticals Inc (ENTA)

American International Group Inc. lessened its stake in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 18.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,921 shares of the biotechnology company’s stock after selling 2,266 shares during the quarter. American International Group Inc.’s holdings in Enanta Pharmaceuticals were worth $803,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Enanta Pharmaceuticals in the 1st quarter worth approximately $112,000. Macquarie Group Ltd. raised its holdings in shares of Enanta Pharmaceuticals by 350.0% in the 4th quarter. Macquarie Group Ltd. now owns 2,700 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 2,100 shares during the period. Financial Gravity Companies Inc. purchased a new position in Enanta Pharmaceuticals in the 4th quarter valued at approximately $181,000. East Coast Asset Management LLC. purchased a new position in Enanta Pharmaceuticals in the 4th quarter valued at approximately $218,000. Finally, LS Investment Advisors LLC grew its stake in Enanta Pharmaceuticals by 56.8% in the 4th quarter. LS Investment Advisors LLC now owns 3,714 shares of the biotechnology company’s stock valued at $218,000 after buying an additional 1,345 shares in the last quarter. 76.15% of the stock is currently owned by institutional investors.

A number of research firms recently weighed in on ENTA. Royal Bank of Canada reiterated a “hold” rating and issued a $80.00 price objective on shares of Enanta Pharmaceuticals in a research note on Wednesday, April 4th. BidaskClub lowered shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 23rd. Oppenheimer began coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, May 24th. They issued a “buy” rating and a $135.00 price objective for the company. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $111.00 price objective for the company in a research note on Thursday, May 3rd. Finally, Roth Capital began coverage on shares of Enanta Pharmaceuticals in a research note on Wednesday. They issued a “buy” rating and a $133.00 price objective for the company. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $83.71.

Enanta Pharmaceuticals stock opened at $116.92 on Friday. Enanta Pharmaceuticals Inc has a 1-year low of $29.50 and a 1-year high of $117.95. The company has a market capitalization of $2.07 billion, a P/E ratio of 128.48 and a beta of 1.07.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.53 by $0.08. The firm had revenue of $44.00 million during the quarter, compared to analyst estimates of $40.77 million. Enanta Pharmaceuticals had a net margin of 31.60% and a return on equity of 18.50%. The business’s revenue for the quarter was up 388.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.28) EPS. equities analysts predict that Enanta Pharmaceuticals Inc will post 3.35 earnings per share for the current fiscal year.

In other news, VP Nathalie Adda sold 4,155 shares of the business’s stock in a transaction on Wednesday, May 16th. The shares were sold at an average price of $105.25, for a total transaction of $437,313.75. Following the completion of the transaction, the vice president now directly owns 8,955 shares in the company, valued at approximately $942,513.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jay R. Luly sold 25,000 shares of the business’s stock in a transaction on Thursday, May 17th. The shares were sold at an average price of $105.83, for a total transaction of $2,645,750.00. Following the transaction, the insider now owns 638,994 shares of the company’s stock, valued at $67,624,735.02. The disclosure for this sale can be found here. Insiders have sold a total of 42,380 shares of company stock valued at $4,222,959 over the last 90 days. Company insiders own 10.56% of the company’s stock.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply